Series A financingSciRhom GmbH closes €63m Series A financ...German iRhom2-targeted antibody specialist SciRhom GmbH has closed an oversubscribed €63m Series A financing that will be used to provide clinical proof of concept in autoimmune disorders. more ➔
AcquisitionLigand Pharma to acquire Apeiron BiologicsAustrian Apeiron Biologics goes to Ligand Pharmaceuticals for US$100m. more ➔
PartnershipEuroscreenFast and GW Vitek announce distr...Belgium-headquarted GCPR-screening specialist EuroscreenFast and Asian distributor GW Vitek have inked a strategic collaboration. more ➔
EMAEMA-Gate: PharmaMar wins suit against EMAThe European Commission has fully upheld the complaint by PharmaMar SA due to conflicts of interest of leading EMA experts in the (non-)authorisation of Aplidin. more ➔
Financing roundNovo Holdings and Abingworth co-lead £90m...Danish Novo Holdings A/S and Abingworth co-led the largest European Series A financing round this year. Together with existing and new investors, they put £90m into cancer ADC specialist Myricx Bio … more ➔
AcquisitionAnacura aquires Ohmx.bioMerger within Ghent, Belgium: Anacura acquires OHMX.bio (both residing in neighborhood), adding multi-omics for drug discovery and diagnostics to its services. more ➔
EMATen drug recommendations by EMA EMA’s human medicines committee (CHMP) recommended ten medicines for approval at its June 2024 meeting. more ➔
Nyoxoa SANyxoah signs a €37.5m loan with the Euro...Nyxoah SA (Euronext Brussels/Nasdaq: NYXH), located in Mont-Saint-Guibert, Belgium announced that it has signed a €37.5m loan facility agreement with the European Investment Bank (“EIB”). The agreement … more ➔
ExpansionNovo Nordisk expands footprint in USA Novo Nordisk realises a major expansion in Clayton, NC (USA). The project will enhance Novo Nordisk’s manufacturing capabilities with more than 1.4 million square feet of new space. more ➔
InvestmentForbion closes first Bioeconomy Fund with... Forbion BioEconomy represents a strategic expansion of Forbion’s investment scope in biotech and in the life sciences sector to address challenges relating to the environment, the growing need for a … more ➔
